LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up
LifeMD announced $199 monthly cash-pay pricing for starter doses of Wegovy and Ozempic, available to new patients for their first two fills through its Weight Management Program. The move follows a partnership with Novo Nordisk and comes hours before LifeMD’s delayed Q3 2025 earnings release, rescheduled for Nov. 17. LFMD shares traded around $4.60 this afternoon, slightly down despite the news.
